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Diagnosing Crohn’s Disease: An Economic Analysis
Comparing Wireless Capsule Endoscopy with
Traditional Diagnostic Procedures
NEIL I. GOLDFARB, B.A., LAURA T. PIZZI, Pharm.D., MPH, JOSEPH P. FUHR, JR., Ph.D.,
CHRISTOPHER SALVADOR, Pharm.D., VANJA SIKIRICA, Pharm.D., 
ASHER KORNBLUTH, M.D., and BLAIR LEWIS, M.D.
ABSTRACT
The purpose of this study was to review economic considerations related to establishing a di-
agnosis of Crohn’s disease, and to compare the costs of a diagnostic algorithm incorporating
wireless capsule endoscopy (WCE) with the current algorithm for diagnosing Crohn’s disease
suspected in the small bowel. Published literature, clinical trial data on WCE in comparison
to other diagnostic tools, and input from clinical experts were used as data sources for (1)
identifying contributors to the costs of diagnosing Crohn’s disease; (2) exploring where WCE
should be placed within the diagnostic algorithm for Crohn’s; and (3) constructing decision
tree models with sensitivity analyses to explore costs (from a payor perspective) of diagnos-
ing Crohn’s disease using WCE compared to other diagnostic methods. Literature review con-
firms that Crohn’s disease is a significant and growing public health concern from clinical,
humanistic and economic perspectives, and results in a long-term burden for patients, their
families, providers, insurers, and employers. Common diagnostic procedures include radio-
logic studies such as small bowel follow through (SBFT), enteroclysis, CT scans, ultrasounds,
and MRIs, as well as serologic testing, and various forms of endoscopy. Diagnostic costs for
Crohn’s disease can be considerable, especially given the cycle of repeat testing due to the
low diagnostic yield of certain procedures and the inability of current diagnostic procedures
to image the entire small bowel. WCE has a higher average diagnostic yield than compara-
tive procedures due to imaging clarity and the ability to visualize the entire small bowel. Lit-
erature review found the average diagnostic yield of SBFT and colonoscopy for work-up of
Crohn’s disease to be 53.87%, whereas WCE had a diagnostic yield of 69.59%. A simple deci-
sion tree model comparing two arms—colonoscopy and SBFT, or WCE—estimates that WCE
produces a cost savings of $291 for each case presenting for diagnostic work-up for Crohn’s.
Sensitivity analysis varying diagnostic yields of colonoscopy and SBFT vs. WCE demonstrates
that WCE is still less costly than SBFT and colonoscopy even at their highest reported yields,
as long as the diagnostic yield of WCE is 64.10% or better. Employing WCE as a first-line di-
agnostic procedure appears to be less costly, from a payor perspective, than current common
procedures for diagnosing suspected Crohn’s disease in the small bowel. Although not ad-
dressed in this model, earlier diagnosis with WCE (due to higher diagnostic yield) also could
lead to earlier management, improved quality of life and workplace productivity for people
with Crohn’s disease. (Disease Management 2004;7:292–304)
Department of Health Policy, Jefferson Medical College, Philadelphia, Pennsylvania, and The Mount Sinai Med-
ical Center, New York, New York.
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INTRODUCTION
CROHN’S DISEASE (CD) is a type of inflamma-tory bowel disease which predominantly
affects the small intestine and colon.1 CD in-
volves a transmural inflammation of the bowel
wall and is characterized as discontinuous ar-
eas of inflammation, ulceration, scarring and
fistualization throughout the GI tract, though
primarily in the ileum, ileocecal region, and
colon.2,3 Patients with CD can generally be cat-
egorized based on the location of the disease:
small bowel alone (30%–35% of cases), small
and large bowel (45%–50% of cases) or colon
alone (20% of cases).2,4
Between 400,000 and 600,000 patients are be-
lieved to have CD in North America, with a re-
ported incidence of 3.1 to 14.6 per 100,000 per-
son-years in North America and a prevalence
ranging from 26 to 198.5 per 100,000 people.5
In the United States, the incidence of CD is ap-
proximately 5 out of 100,000 and the prevalence
is estimated to be 50 out of 100,000.6 Although
estimates of CD incidence vary across studies,
all studies point to a substantial increase in
cases of the disease over the past 30 years.1 Fac-
tors contributing to this increase are believed
to include heightened provider and consumer
awareness of Crohn’s Disease, improved diag-
nostic testing, and changes in diet and behav-
ioral risk factors. While CD affects both sexes,
it may be more predominant in women, with
the percentage of female cases ranging from
48% to 66%.5 Although CD can occur at any
age, cases cluster within two distinct age
ranges: 15–25, and 50–80.1,7,8 The highest inci-
dence of CD is seen in young adults, for whom
chronic debilitating disease has broad societal
implications9 both in terms of lifetime eco-
nomic burden of disease, and lost productivity.
Clinical presentation
The clinical presentation of CD is often non-
specific but insidious, with symptoms fluctu-
ating throughout the course of the disease.2
Symptoms may include diarrhea, abdominal
pain, weight loss, fever, and blood in the stool.
Clinical presentation is influenced by the pat-
tern of injury, including the extent and sever-
ity of mucosal disease.9 Extraintestinal mani-
festations of CD include rashes, arthritis, and
uveitis as well as perirectal disease.2 Compli-
cations can include malnutrition, malabsorp-
tion, small bowel obstruction, anemia, malig-
nancy of both the intestine and extra-intestinal
sources, and bowel perforations.2,4 Less com-
mon, but serious complications include devel-
opment of strictures of the intestinal tract lead-
ing to obstructive symptoms or fistulae.
Treatment
Treatment for CD can involve symptom
management and/or control of disease activ-
ity. Medical therapies to limit symptoms in-
clude antidiarrheals, antispasmodics, and an-
tibiotics. The inflammatory process can be
modulated with the use of steroids (topical, en-
teral or parenteral), anti-inflammatory, an-
timetabolite and/or anti-TNF therapies. Dis-
ease remission also may be induced with
surgical treatment.10,11 Although surgical re-
section of the involved intestinal segment is cu-
rative in some cases, recurrence of disease is
common. Approximately 75% of patients with
CD will need surgery at some point in their
lives. In addition, 40%–50% of those with re-
current symptoms after a first operation will
need a second operation, while 10%–30% will
require a third operation.12 Although rarely fa-
tal, CD is associated with high patient morbid-
ity and, due to the early age of onset, can pro-
foundly affect the patient’s physical, social,
professional and emotional well-being.13,14
Economic impact
In addition to its clinical consequences, CD
carries a significant economic impact,15–17 with
the total cost of illness estimated to exceed $1.7
billion annually in the United States.18 These
costs can be classified as direct, indirect, or in-
tangible (Fig. 1). Direct costs are defined as ex-
penses incurred due to the disease. Examples
can include diagnostic work-up, medications,
hospitalizations, physician time, surgery and
complications associated with each. The esti-
mated direct cost of CD in the United States
during 1990 was $1.0–$1.2 billion,19 and the
medical cost of managing CD has been esti-
mated at $9,197 ($US 1996) per patient with CD
annually.18 The initial diagnostic work-up rep-
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resents approximately 1.5%–7.8% of the total
medical cost, and ranges between $140 and
$650 (1996 US$).15 Contributors to the direct
cost for the initial diagnostic work-up include
multiple endoscopic procedures, preparations
for the procedures, equipment fees, imaging
studies, radiology, laboratory charges, and per-
sonnel fees.
Indirect costs include lost productivity of pa-
tients and caregivers, transportation, and lodg-
ing expenses associated with receiving diag-
nostic testing and medical care. More severe
cases of CD could render the patient disabled
and thus significantly impair productivity both
at work and at home. Between 15% and 24% of
patients are disabled after having CD for five
or more years.18 The cost of CD-related dis-
abilities has been estimated to be $0.6–$1.1 bil-
lion annually, with approximately 5%–10% of
all patients with inflammatory bowel disease
“so greatly incapacitated that they are unable
to work.”14,18
Intangible costs are associated with pain,
anxiety, depression, altered body image, inter-
ference in interpersonal relations, sexual dys-
function and an overall decreased quality of
life.18,20 Since CD is a chronic disease that typ-
ically has an early age of onset, patients often
suffer from the disease throughout most of
their adult life and will need to develop cop-
ing skills in order to positively maintain their
professional, social and personal lifestyles.18,20
Establishing a diagnosis
Procedures used to diagnose CD include
imaging studies, radiologic tests, endoscopy,
and serum antibody tests.3,21,22 Multiple tests
and cycles of repeated testing are common in es-
tablishing a diagnosis.23 Because none of these
tools represent a gold standard, the diagnosis is
usually established through assessment of the
clinical presentation in combination with radio-
graphic, endoscopic and, if possible, histologic
findings (Fig. 2).2,7,8,24 The National Cooperative
Crohn’s Disease Study reported an average lag
time of 36 months between the onset of symp-
toms and the presence of abnormal findings on
diagnostic evaluation.25
Initial diagnosis of CD has been difficult due
to the limited diagnostic abilities of traditional
technology. Despite the availability of a wide
array of diagnostic tools,2,3,21,22,26,27 early mu-
cosal changes often cannot be detected using
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FIG. 1. Ishekawa diagram of costs associated with the diagnosis of Crohn’s disease.
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FIG. 2. Current and proposed algorithm for the diagnosis of Crohn’s disease.
traditional testing methods (particularly if
these changes are located in the small bowel).
Though 75% of patients with CD have small
bowel involvement, more than one third have
disease isolated to the small bowel.28
As a result of these diagnostic limitations, pa-
tients may be labeled as having an irritable
bowel, and treatment with directed therapies
that can control symptoms and place the CD in
remission may not be initiated in a timely man-
ner. (Conversely, patients with irritable bowel
syndrome can be incorrectly labeled as having
CD.) Since early intervention has a greater like-
lihood of inducing remission, clearly there is a
strong need for a gold standard test to correctly
diagnose CD of the small bowel in its early
stages.
Wireless capsule endoscopy (WCE) (Given
Imaging Limited™, Yoqneam, Israel) received
FDA clearance in 2001 for diagnosing diseases
and disorders of the small intestine. The M2A®
capsule, measuring 11  26 mm, obtains direct
mucosal images from the entire small bowel.29
Images are transmitted by the capsule to a
recording belt and are subsequently down-
loaded to a viewing station for review by a cli-
nician. The early indications for WCE initially
were to determine the source of occult or ob-
scure gastrointestinal (GI) bleed, chronic GI
blood loss or recurrent overt bleeding in pa-
tients with negative results of endoscopic ex-
aminations, and these indications were based
upon initial published data.30 However, recent
literature has shown that WCE provides im-
proved imaging of the small bowel,31,32 and
that WCE has higher diagnostic yields for CD
in comparison to push enteroscopy, small
bowel series31,33 and enteroclysis.34 With the
high occurrence of CD in the small bowel and
terminal ileum, WCE has emerged as a poten-
tial candidate for the initial diagnosis of CD.
Based on a meta-analysis of 32 independent
studies submitted to the FDA by Given Imag-
ing, the FDA agreed to remove the “adjunctive
tool” qualifier from the indications for WCE,
making it available as a first-line tool in the
imaging of the small bowel.32,35
In November 2003, Blue Cross and Blue
Shield Association’s Medical Advisory Panel
determined that the use of capsule endoscopy
for the initial diagnosis of patients with sus-
pected CD meets TEC (Technology Evaluation
Center) criteria. The TEC bases its assessments
on clinical and scientific evidence and evalu-
ates whether a technology improves health out-
comes such as length of life, quality of life and
ability to function.
The objective of the present study was to ex-
amine the clinical and economic factors associ-
ated with the current diagnosis of CD, and to
compare the costs of a diagnostic algorithm em-
ploying WCE with the currently typical diag-
nostic algorithm using a decision tree model.
MATERIALS AND METHODS
A comprehensive evaluation of peer-re-
viewed published medical literature was con-
ducted to review studies involving diagnostic
procedures for CD. MEDLINE and CINAHL
databases were used, with a search strategy
that included the following keywords: “wire-
less capsule endoscopy,” “video capsule en-
doscopy,” “M2A capsule,” “diagnosis,” “dif-
ferential diagnosis,” “cost,” and “Crohn’s
Disease.” Separate searches were conducted 
on each of the potential diagnostic techniques
that can be used in the diagnosis of CD:
colonoscopy, endoscopy, magnetic resonance
imaging (MRI), ultrasound (US), computed to-
mography (CT), small bowel follow through
(SBFT), enteroclysis and serology tests. Because
WCE was approved in August 2001, all
searches on this device were limited to the 
English language with publication dates be-
tween January 2000 and February 2004. Longer
search ranges were used for older diagnostic
tools such as colonoscopy. References cited by
the relevant articles were identified and re-
viewed (snowball technique). The search in-
cluded studies of patients with suspected CD,
and excluded studies involving patient popu-
lations with a history of previous inconclusive
diagnostic work-up. Documents on the regula-
tory status of the WCE device, evidence-based
guidelines from national professional organi-
zations, and abstracts presented during Diges-
tive Disease Week (DDW) 2003 were also re-
viewed.
A decision tree model was developed using
TreeAge (Data Pro 4.0) software and Microsoft
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Excel spreadsheets. A payor perspective was
taken, looking at direct medical costs for diag-
nostic testing. Cost data represented average
Medicare reimbursements (technical and pro-
fessional fees) for diagnostic procedures.36–38
RESULTS
Review of diagnostic test options and yields
1. Small bowel follow through (SBFT). Small
bowel follow through (SBFT) is an established
method for detecting and evaluating the pres-
ence of CD of the small bowel. Studies have
shown its diagnostic yield in practice to be ap-
proximately 58% when CD is present.39,40 The
primary advantage of SBFT is its ability to de-
tect transmural thickening while being safer
than colonoscopy. In addition, SBFT can be
used in younger patients and requires less to-
tal time than enteroclysis.21,41 However, SBFT
may miss changes of early Crohn’s ileitis; it
may be difficult to visualize and localize stric-
tures, difficult to decipher whether lesions are
raised or flat, and there is no ability to biopsy
inherent to this procedure.21,39–41 Finally, with
SBFT or any study involving the use of barium,
there is the risk of radiation exposure and con-
stipation.42
2. Enteroclysis. A number of studies suggest
diagnostic superiority of enteroclysis, based on
the ability of the evaluator to channel the con-
trast media into the bowel areas rather than
having the patient ingest it as in SBFT.41,43 Al-
though enteroclysis may be more sensitive than
SBFT, it has been reported to require a longer
procedure time, involves more radiation expo-
sure than routine small bowel series,44 and is
more invasive since the physician must insert
a tube into the patient’s small intestine through
the nose or mouth.21,34,45,46 Enteroclysis is com-
monly used in Europe. However, in the United
States enteroclysis is not routinely available at
many centers and is thus not widely used in
the evaluation of Crohn’s disease.
3. Colonoscopy. Colonoscopy is particularly
useful in detecting colonic CD. It allows for vi-
sualization of the entire colon as well as the ter-
minal ileum. In addition, the colonoscopy of-
fers the inherent ability for conducting biopsies
during the procedure.3 However, colonoscopy
has several major disadvantages: (1) it is more
invasive to the patient21,22,47; (2) it requires the
use of intravenous conscious sedation which
incurs extra costs and risks; and (3) the termi-
nal ileum may be visualized only 70%–80% of
the time, perhaps making it a suboptimal
choice for detecting lesions in the small bowel,
and endoscopic biopsies are not always possi-
ble.40,48–50 Given the latter, colonoscopy is gen-
erally not used alone in diagnosing CD; rather,
it is typically conducted in combination with
WCE, SBFT, or enteroclysis.51
4. Single contrast barium enema (SCBE) and air
contrast barium enema (ACBE). Barium enemas
were once commonly used to evaluate patients
with suspected colitis. Air contrast studies pro-
duce results with greater detail and are able to
identify small ulcerations more frequently than
single contrast studies. Barium enemas may
also be used to evaluate the terminal ileum
with reflux of barium into the ileum in retro-
grade fashion. Though this can be diagnostic
for mucosal changes of CD, approximately 10%
of studies will result in barium reflux into the
small bowel, thus limiting the exam to the colon
only.21
5. Computed tomography (CT). Computed to-
mography (CT) offers the ability to decipher
the various types of patterns in which the dis-
ease may present21 and is useful for showing
the site and cause of high-grade obstruction in
patients.43 However, in order for CT to detect
disease, tissue changes must extend the entire
bowel wall, and include thickening. Solitary
mucosal disease is not detected by this method.
In addition, oral contrast given prior to the
exam must reach the suspected area to provide
an adequate exam. Its role in the initial diag-
nosis is limited due to the likelihood of false
negatives resulting from an inability to detect
early mucosal changes. More recently, the ad-
dition of multidetector machines to this exam
has allowed the development of an improved
technology called CT enterography. There are
few published studies involving this technique,
but preliminary data suggest improved detec-
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tion of bowel wall thickening and the presence
of small bowel stenoses.21 Although this tech-
nique is improved for extra-luminal findings,
it remains less sensitive than WCE for the de-
tection of small bowel disease.33
6. Magnetic resonance imaging (MRI). Cur-
rently, magnetic resonance imaging (MRI) has
a limited role in the evaluation of initial CD, in
part due to limited accessibility and high
costs.52 It is similar to CT in its cross-sectional
imaging technique. It offers advantages over
CT, especially in evaluation of the perineal re-
gion, and may have superior tissue contrast, no
radiation exposure, and ability to select various
cross-sectional planes.53 Its main disadvantage
in comparison to CT is poorer resolution.
7. Serology (pANCA). Serology often is reserved
as a supplemental tool to help rule-in or rule-out
CD in cases which are questionable. There are
two main tests that can be used; both rely on de-
tecting serum antibodies. The perinuclear anti-
neutrophil antibody (pANCA) and the anti-Sac-
charomyces cervisiae antibody (ASCA) are used
to distinguish between Crohn’s disease and ul-
cerative colitis (UC). Due to the low sensitivity
of these tests, approximately 65% of patients
with UC have pANCA in their blood, and ap-
proximately 40% of CD patients are ASCA pos-
itive.21,22 However, CD patients with only
colonic involvement may be pANCA positive
and ASCA negative.21
8. Wireless capsule endoscopy (WCE). Studies
conducted to date have shown WCE to have an
equivalent or higher diagnostic yield than
other procedures,26,31,33,34,54–56 which suggests
a reduced number of diagnostic procedures re-
quired to make an initial diagnosis of CD. The
visual clarity is higher than that of barium stud-
ies.33 Like small bowel series or CT, WCE does
not offer the ability to biopsy, but it can detect
areas of abnormality for follow-up biopsy.
WCE is more sensitive than other diagnostic
procedures including barium studies and CT
enterography in detecting abnormalities in the
small bowel.31,32,35,55 In addition, it is less in-
vasive than other procedures, thus promoting
patients’ compliance. A limitation of WCE is its
potential for retention in the bowel due to stric-
tures. The incidence of retention in work-up for
suspected CD is unknown. However, retention
occurred in 0.75% of cases from reported clin-
ical trials, mostly performed for the evaluation
of obscure bleeding.57 These cases of retention
occurred secondary to small bowel tumors or
strictures. The device is contraindicated in pa-
tients with known or suspected strictures, pa-
tients with pacemakers or other implanted 
electromedical devices, and patients with 
swallowing disorders.58 Patients with poor GI
motility may not pass the capsule or the cap-
sule might not visualize the entire small bowel.
Patients with swallowing problems may not be
able to swallow the capsule.30,59
RESULTS OF THE DECISION 
TREE MODEL
A decision tree model was constructed to
compare typical current diagnostic work-up to
work-up employing WCE as a first-line diag-
nostic test (Fig. 3). Typical work-up was de-
fined as colonoscopy and SBFT based on con-
sultation with clinician experts and literature
review. Patients that fail to have a diagnosis
made with these initial procedures (colonos-
copy/SBFT) will then incur the cost of “other
diagnostic tests.” The model also takes into ac-
count the complications (ie, perforations) asso-
ciated with colonoscopy/SBFT, as well as 
the associated cost of such events. The proba-
bility of perforation in patients undergoing
colonoscopy was found to be 0.03% and the
cost for treating colonoscopy-induced perfora-
tions was $20,000 (US$ 1990).60,61 In the com-
parative arm, patients would undergo WCE as
the first-line procedure for the diagnosis. As
with the current practice arm, patients that
failed WCE would then incur the cost of “other
diagnostic tests.” This arm also takes into ac-
count the probability of capsule retention as
well as the associated cost for overall retrieval.
The probability of capsule retention was esti-
mated to be 0.75% at most.62 The diagnostic
failure rates for both procedures were based on
the diagnostic yields found in the literature.
The pooled yield of WCE, for all pathologies,
across available studies, was found to be
69.59%, while the pooled diagnostic yield of
colonoscopy/SBFT was estimated to be 53.87%
(Table 1). The cost of “other diagnostic tests”
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was derived from the diagnostic work-up in
the Hay and Hay study. In order to employ
more current figures, the numbers given in the
Hay and Hay study (US$ 1990) were converted
to 2002 dollars by multiplying them by the an-
nual increases in the medical care services com-
ponent of the Consumer Price Index for the
years 1990–2002.6
Physician and facility costs associated with
each procedure were determined from reim-
bursement figures based upon Medicare Fee
Schedule as determined by CMS.36–38 The total
costs of both diagnostic arms (colonoscopy/SBFT
versus WCE) were calculated and compared.
As shown in Figure 3, the total cost for pa-
tients undergoing colonoscopy/SBFT was cal-
culated to be $1,838 compared to $1,547 for pa-
tients who underwent WCE. Thus, the net
savings of using WCE, from a payor perspec-
tive, was estimated at $291 per case initially
presenting for work-up.
A sensitivity analysis was conducted to de-
termine the robustness of our model to varia-
tion in assumptions in the range of diagnostic
yields found in the published literature. Diag-
nostic yields of colonoscopy/SBFT and WCE
were varied across the ranges as reported in the
literature (Table 1). As long as the diagnostic
yield for WCE was 64.10% or greater, WCE was
the lower cost diagnostic option regardless of
the diagnostic yield of colonoscopy/SBFT
(across the range of yields reported in the lit-
erature, 45.24%–61.67%). WCE also was the less
costly first-line test, when comparing within
the same diagnostic categories (ie, comparing
high to high, average to average, or low to low).
In addition, a separate analysis was con-
ducted comparing enteroclysis and colonoscopy
versus WCE. The pooled diagnostic yield for en-
teroclysis and colonoscopy was found to be
40.04% with the cost of the combined procedure
being $840. All other figures in the model re-
mained constant. The total cost for diagnosing
Crohn’s disease using enteroclysis and colono-
scopy was $2,165, compared to $1,547 for WCE.
Thus, the net savings of using WCE, from a
payor perspective, was estimated at $618 per
case initially presenting for work-up.
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No Perforations
0.9997
Perforations (3)
0.0003
1,838.40
0.4613
Positive
Diagnosis (2)
Failed
Diagnosis
SBFT
and Colonoscopy
Suspected
Crohn’s in Small
Bowel
0.5387
817.84
20817.84
Perform
Other Test (1)
1.0000
3017.84
No Retention
Wireless Capsule Endoscopy 0.9925
Retention (6)
0.0075
0.3041
Positive
Diagnosis (5)
Failed
Diagnosis
0.6959
733
20733
Perform
Other Test (4)
1.0000
2933
1,547.00
Estimated costs for “other tests,” derived from the Hay and Hay study and adjusted to 2003 US dol-
lars, was $2200. Medicare costs for SFBT and Colonoscopy were $817.84. Medicare costs for WCE
were &733.00. Costs for perforations and retention were 
estimated to be $20,000.
1Total cost of other tests plus Medicare cost for SBFT and colonoscopy
2Total cost for positive test from SBFt and Colonoscopy
3Total cost for perforations and Medicare cost for SBFT and Colonoscopy
4Total cost of other tests plus Medicare cost for WCE
5Total cost for positive test from WCE
6Total cost for perforations and Medicare cost for WCE
FIG. 3. Economic analysis decision tree.
A sensitivity analysis was conducted for 
this model as well. Diagnostic threshold for
WCE was determined while using the highest
diagnostic yield for enteroclysis/colonoscopy
(58.73%). As long as the diagnostic yield for
WCE was 60.13% or greater, WCE was the
lower cost diagnostic option, regardless of the
diagnostic yield of colonoscopy/enteroclysis
(across the range of yields reported in the lit-
erature, 36.69%–58.73%). As with the previous
model, WCE was also the less costly first-line
test when comparing within the same diag-
nostic categories (ie, comparing high to high,
average to average, or low to low).
Certain assumptions were made in the cre-
ation of these models. Patients were assumed
to be previously undiagnosed, present without
strictures, and have disease detectable in the
small bowel.2 The cost of additional tests used
in the model was $2,200 and was assumed to
be the same in both arms.3 The cost of retrieval
of capsule was assumed to be similar to the cost
for treating colonoscopy-induced perforations
through surgery ($20,000 USD), when in fact
capsule retrieval could be much lower due to
spontaneous excretion or the ability to remove
the capsule endoscopically. Therefore, this is a
conservative estimate. It should be noted that
surgical intervention for a retained capsule is
likely to identify a diseased area (such as a tu-
mor or stricture), while a repair for colonos-
copy-induced perforation typically does not.
The model does not address the added value
of WCE for these rare events.4 Patients undergo
both colonoscopy and SBFT in the control arm.
Current clinical practice varies significantly,
but in all likelihood literature indicates that, if
anything, this model conservatively estimates
costs of current (without WCE) standard diag-
nostic process.
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TABLE 1. DIAGNOSTIC YIELDS OF DIAGNOSTIC PROCEDURES USED IN CROHN’S DISEASE
Number Total number
diagnosed evaluated Diagnostic yield
WCE
Fireman et al.26 12 17 70.59%
Chong et al.57 7 9 77.78%
Eliakim et al.33 14 20 70.00%
Costamagna et al.31a 9 20 45.00%
Mow et al.56b 20 50 40.00%
Hara et al.55 12 19 63.19%
Buchmann et al.64 15 23 65.22%
Bloom et al.65 8 16 50.00%
Tabibzadeh et al.66 35 44 79.55%
Sum 103 148 69.59%
SBFT
Bernstein et al.40 15 26 57.69%
Halligan et al.39 71 121 58.68%
Buchmann et al.64 15 23 65.22%
Bloom et al.65 9 16 56.25%
Sum 110 186 59.14%
Enteroclysis
Bernstein et al.40 15 26 57.69%
Cirillo et al.67 61 165 36.97%
Maglinite et al.68 43 138 31.16%
Sum 119 329 36.17%
Colonoscopy
Halligan et al.39 22 37 59.46%
Coremans et al.46 48 110 43.64%
Bloom et al.65 8 16 50.00%
Sum 78 163 47.85%
aCD diagnosis “suspicious” in eight others—not included in analysis.
bCD diagnosis “suspicious” in ten others—not included in analysis.
DISCUSSION
Literature review demonstrates that a num-
ber of tools are currently available for estab-
lishing a diagnosis of CD. Our model illustrates
that the higher diagnostic yield of WCE could
translate into fewer diagnostic procedures for
CD, reducing total diagnostic costs.
This finding is further supported by the con-
servative diagnostic yields employed within
the model. We used 69.59% and 53.87% for the
diagnostic yields of WCE and colonoscopy/
SBFT, respectively. However, a meta-analysis
of 32 independent studies submitted to the
FDA by Given Imaging indicated a diagnostic
yield of WCE of 71%, with other diagnostic
tests inclusive of SBFT, push-enteroscopy, CT
scan, abdominal x-ray, angiography and inter-
operative enteroscopy having a pooled diag-
nostic yield of 41% across a variety of small
bowel conditions.32,63
Our analysis focuses primarily on costs from
a payor perspective. It therefore does not con-
sider the additional potential benefits of earlier
diagnosis associated with use of WCE, which
remain to be studied. For example, since WCE
is less invasive compared to colonoscopy/
SBFT and does not require the use of sedatives,
anesthetics, or other medications, there is ex-
pected to be a psychological benefit which has
not yet been quantified.
The societal implications of WCE include
earlier diagnosis that can lead to earlier man-
agement and improved clinical outcomes.
Through our literature review, we were able to
estimate the number of diagnostic procedures
conducted before CD diagnosis was made, and
found this to be approximately 4.5 (Table 2).
This finding is consistent with a long duration
of symptoms prior to diagnosis. Earlier diag-
nosis holds the promise of earlier medical man-
agement and a reduced number of surgical in-
terventions. Earlier management also is likely
to improve patients’ quality of life and reduce
lost work productivity. These factors are ex-
pected to add to the overall cost savings of us-
ing WCE for diagnosing CD.
In addition, a negative capsule exam carries
a diagnosis unlike a negative small bowel se-
ries. WCE has demonstrated a low miss rate of
0.5% for ulcers in the small bowel compared to
78.7% for the comparison technologies. There-
fore, a negative capsule exam is a true negative
and small bowel Crohn’s disease can effec-
tively be dismissed from the differential diag-
nosis of a patient’s symptoms. Therapy can
then be directed toward another diagnosis such
as irritable bowel syndrome.
The decision tree model presented in this
analysis has several limitations. First, we did
not employ a statistical meta-analysis for pool-
ing the diagnostic yields available in the liter-
ature. Rather, we used an average of available
yields, which was weighted based on the num-
ber of patients participating in each study. As
such, our method fails to account for possible
heterogeneity between the studies. However,
given the limited number of studies assessing
the yields of the included diagnostic alterna-
tives, we decided to compute yields which
were reflective of all available literature on the
topic, rather than a statistically selected group
of studies (which would have been the case had
meta-analysis been used).
In addition, estimated diagnostic yields do
not take into account the conjoint yields of tests
used in combination. In pooling yields for SBFT
and colonoscopy, the estimated combined yield
is in fact lower than the yield of SBFT alone.
However, the SBFT studies appear to signifi-
cantly overestimate yields by including many
patients with advanced disease. The model also
uses a fairly conservative literature-based esti-
mate of the costs of additional diagnostic test-
ing associated with an undiagnosed case. It is
quite possible that the lifetime (or longer-term)
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TABLE 2. AVERAGE NUMBER OF PROCEDURES
PER PATIENT PRIOR TO WCE
Number of
previous Number of
Study procedures patients
Costamagna et al.31 210 22
Liangpunsakul et al.34 137 40
Eliakim et al.33 48 20
Herrerias et al.69 59 21
Fireman et al.26 92 17
Total 546 120
Average number 4.55
of procedures
per patient
costs of diagnostic workup are significantly
greater than what was used in the model, and
any greater figure would only strengthen the
case for WCE’s early use in CD work-up. Al-
though the model also does not incorporate the
costs of confirmatory diagnostic testing (eg, bi-
opsy to confirm a diagnosis by tissue histol-
ogy), this testing is not clinically necessary if a
diagnosis of CD has in fact been established.
Finally, our model assumes that colonoscopy
is not conducted with WCE. Although many
clinicians would argue that colonoscopy would
be conducted as a matter of routine during the
work-up process, we excluded it from the WCE
arm because (1) studies have demonstrated that
WCE alone has a sufficiently high yield such that
other tests would not be required; (2) WCE is
now accepted as a first-line method for imaging
the small bowel; (3) the model is focused on ini-
tial diagnosis of CD for which there is expected
to be minimal chance of retention (eg, due to
minimal transmural thickening); and (4) the less
invasive nature of WCE alone renders it more
appropriate from the patient’s perspective.
CONCLUSION
This economic analysis shows that employ-
ing WCE would most likely be less costly, from
a payor perspective, than current diagnostic
practice. WCE is an appropriate first-line test
for diagnosing CD and offers savings by re-
ducing the number of tests required to estab-
lish a diagnosis. Through the earlier diagnosis
made possible by WCE, patients are likely to
receive appropriate treatment sooner than they
would have under other diagnostic scenarios,
and experience corresponding gains in quality
of life.
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